iShares气候意识与转型MSCI美国ETF USCL 深 沪
已收盘 05-08 16:00:00 美东时间
82.8325
+0.374
+0.45%
华盛通- 最 高82.8325
- 今 开82.655
- 成交量 17股
- 最 低 82.8325
- 昨 收 82.4584
- 总市值 253.47万
- 52周最高 82.8325
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 68.3009
- 委 比 -9.09%
- 总股本 3.06万
- 历史最高 82.8325
- 量 比 0.02
- 振 幅 0.00%
- 历史最低 46.1911
- 每 手 1
- 风险率 3.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股盘后 | Bloom Energy涨13.83%，Credo Technology涨9.23%
Bloom Energy涨13.83%；Credo Technology涨9.23%；Sandisk Corporation涨2.73%
04-14 06:10
美股盘后 | 瑞穗金融涨2.77%，罗克韦尔自动化涨2.66%
瑞穗金融涨2.77%；罗克韦尔自动化涨2.66%；Ares Management Corporation涨2.48%
04-01 06:10
BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1
BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1 Sarepta Therapeutics Inc SRPT.O : SAREPTA ANNOUNCES FIRST CLINICAL DATA FROM SIRNA PIPELINE TARGETING FSHD1 AND DM1 SAREPTA THERAPEUTICS INC - SIRNA ACHIEVES HIGH MUSCLE CONCENTRATIONS WITHOUT DOSE LIMITING TOXIC
03-25 20:29
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Austin, Texas, United States, March 24th, 2026, FinanceWire Soligenix(NAS...
03-25 00:30
BRIEF-Aro Biotherapeutics Reports Positive Phase 1B Topline Results For Abx1100, A Muscle-Targeted Gys1 Sirna, In Patients With Late-Onset Pompe Disease (Lopd)
BRIEF-Aro Biotherapeutics Reports Positive Phase 1B Topline Results For Abx1100, A Muscle-Targeted Gys1 Sirna, In Patients With Late-Onset Pompe Disease (Lopd) March 17 (Reuters) - ARO BIOTHERAPEUTICS REPORTS POSITIVE PHASE 1B TOPLINE RESULTS FOR ABX1100, A MUSCLE-TARGETED GYS1 SIRNA, IN PATIENTS WI
03-17 20:31
BRIEF-TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
BRIEF-TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Feb 23 (Reuters) - Protara Therapeutics Inc TARA.O : TARA-002 DEMONSTRATES 68% COMPLETE RESPONSE RATE AT SIX MONTHS IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER PROTA
02-24 06:28
BRIEF-Northstrive Biosciences Signs Definitive License Agreement For Commercialization Of El-22 And El-32
BRIEF-Northstrive Biosciences Signs Definitive License Agreement For Commercialization Of El-22 And El-32 Feb 11 (Reuters) - PMGC Holdings Inc ELAB.O : NORTHSTRIVE BIOSCIENCES SIGNS DEFINITIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF EL-22 AND EL-32, A MYOSTATIN-ENGINEERED PROBIOTIC FOR MUSCLE PRE
02-11 20:46
BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint
Dec 17 (Reuters) - PFIZER: PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVAL PFIZER: PATHOLOGIC COMPLETE RES...
2025-12-17 19:45
BRIEF-Anktiva® With Bcg Demonstrates 96% Survival From Bladder Cancer
Dec 16 (Reuters) - Immunitybio Inc IBRX.O: ANKTIVA® WITH BCG DEMONSTRATES 96% SURVIVAL FROM BLADDER CANCER AT THREE YEARS WITH MEDIAN SURVIVAL NOT YET REACHED IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-...
2025-12-16 22:10
BRIEF-Wave Life Sciences Announces Positive Interim Data From Phase 1 Inlight Trial Of WVE-007 For Obesity
Dec 8 (Reuters) - WAVE Life Sciences Ltd WVE.O: WAVE LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 1 INLIGHT TRIAL OF WVE-007 (INHBE) FOR OBESITY; SINGLE DOSE RESULTED IN IMPROVEMENT IN BOD...
2025-12-08 20:31
